Thermo Fisher Scientific

We also repurchased $1.0 billion of stock.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Equity in earnings losses of unconsolidated entities impairments of long-lived assets and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments settlements of pension plans, and the early retirement of debt.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations ability to generate cash for use in acquisitions and other investing and financing activities.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions, transaction-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Delivered excellent operational performance in the quarter demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Established a strategic collaboration with OpenAI to further increase the use of artificial intelligence (AI) across our operations, products and services to accelerate scientific breakthroughs, enhance drug development and drive greater productivity.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Continued to successfully execute our capital deployment strategy.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

During the quarter, we advanced our strategic position by completing the acquisitions of our Filtration and Separation business from Solventum, an excellent complement to our bioproduction capabilities, and Sanofi s Ridgefield, New Jersey, sterile fill-finish site, expanding our U.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

(b) Adjusted results exclude certain third-party expenses, principally transaction integration costs, charges credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges credits for pre-acquisition litigation and other matters, gains losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges credits for pre-acquisition litigation and other matters, net gains losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Equity in earnings losses of unconsolidated entities impairments of long-lived assets and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments settlements of pension plans, and the early retirement of debt.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions, transaction-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings.

SEC original ↗Thermo Fisher Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025